Close Menu
    What's Hot

    Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    August 17, 2026

    Athora To Sell German Business to Frankfurter Leben

    August 17, 2026

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 17, 2026

      Athora To Sell German Business to Frankfurter Leben

      August 17, 2026

      Talcott Financial Group, Goldman Sachs Launch West Grove Re

      August 5, 2026

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026

      Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 17, 2026

      Athora To Sell German Business to Frankfurter Leben

      August 17, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    The Development of the European Life Settlement Association’s Code of Practice

    Secondary Life Markets October 12, 2022By Simon Erritt
    Code of Practice
    Share
    Twitter LinkedIn Email

    The European Life Settlement Association (“ELSA”) was established in May 2009 to set standards for the European life settlement industry and to promote transparency by providing accurate, authoritative information to its investors.

    ELSA’s founding members recognised that the consistent application of best practice was fundamental to the continued prosperity of the industry and the protection of its investors, and quickly sought to collate, refine, document and highlight this best practice.

    Work began on the first edition of its code of practice (the “Code”) in October of that year and it was completed nine months later in July 2010. As Patrick McAdams, then ELSA’s chair, said at the time, “Our Code is a living framework, intended both to encourage and reflect the development of the European life settlement industry in the years ahead. As the market continues to mature, the Code will be updated to ensure that it continues to best serve the needs of the life settlement investor.”

    Twelve years and six editions later, that message still rings true. The current edition of the Code, which ELSA expects to update again this year, is available at https://www.elsa-sls.org/code-of-practice/.

    Development

    The development of the Code is perhaps best summarised by the edition history presented in the Code itself:

    Edition Date Key Features
    1.0 Oct 2009 First draft.  Organised into general provisions and sections on education, transparency, policy origination, competition, consumer choices, suitability, conflicts of interest and priority of clients’ interest.
    1.1 May 2010 Second draft.  Reorganised into asset management and disclosure, risk mitigation, suitability, and transparency.
    1.2 Jun 2010 Third draft.  Reorganised into asset origination, asset and risk management, and managing the investor relationship.
    1.3 Jul 2010 First published edition.  Page of contents added.  Minor textual changes.
    2.0 Sep 2012 Reorganised into product design, disclosure and reporting, and sales and marketing.
    3.0 May 2013 Separated into requirements and guidance.  Additional standards added reflecting “Big 4” auditing practice.
    4.0 Nov 2016 Introductory sections revised.  Additional standards added relating to COI increases, valuation, performance attribution, performance fees, data security, medical record updates, external data sources, and overhead and leverage disclosure.
    5.0 May 2018 Performance attribution and loan/(re)insurance disclosure reworded.  Key portfolio information and portfolio breakdown reporting revised.
    6.0 Jan 2021 Extensive textual changes based on committee members’ comments.  Member conduct section added.  Guide and “Comply or Explain” procedure created.

    Usage and Reception

    ELSA members that are product designers, managers or distributors must comply with the required elements of the Code and are expected to comply with its guidance. ELSA members that are not product designers, managers or distributors are expected to encourage the Code’s use in the products with which they are associated.

    ELSA members certify their compliance with the Code when they apply for membership and annually thereafter. Failure to comply with the Code may ultimately result in the member being asked to resign from the association.

    Members typically reference their membership of ELSA and, by extension, their compliance with the Code in marketing materials, and may use the Code as a basis of discussions with prospective investors; the Code has also been presented and favourably received in ELSA’s meetings with European regulators, including the UK’s FCA, Luxembourg’s CSSF, and Ireland’s CBI.

    Challenges

    Spreading awareness of the existence and content of the Code is a key challenge. Membership in ELSA, and therefore compliance with the Code, remains voluntary. Opportunities to promote the Code, such as this article, are always very welcome.

    As the industry has grown so has the Code, and the current edition runs to fourteen pages of densely worded text. To make it more accessible, particularly to investors looking at the market for the first time, ELSA created a shorter, three-page summary of the principles guiding the formation of the Code, which is available alongside the Code itself at https://www.elsa-sls.org/code-of-practice/.

    To avoid stifling innovation and to bring the Code in line with other international standards, ELSA also introduced a new “Comply or Explain” procedure with the current edition. This allows members, in exceptional circumstances, to request from ELSA’s membership committee an exemption from one or more practices required by the Code. If granted, the member must prepare a disclosure statement, which must be made available to all its existing and prospective investors on request and presented alongside the Code when shared. Viewed by some commentators as potentially weakening the Code, the opposite has been ELSA’s experience: The limited number of exceptions requested to date have highlighted unclear or unqualified wording in the Code that can be refined in the next edition.

    Refinement

    As noted above, ELSA expects to update the Code again this year. One area it is currently looking into is that of performance fees, making sure that the existing wording is clear as it relates to open-ended as well as closed-ended structures.

    A second relates to how regularly life expectancy estimates should be updated. A number of products in the market are less reliant or wholly non-reliant on life expectancy estimates, and the existing wording may benefit from qualification.

    Conclusion

    ELSA believes the Code is among the most comprehensive documents of its type in the life settlement industry. It is detailed throughout and complex in places, reflecting the relative complexity of the market. For over a decade, it has provided prospective investors with a framework for their due diligence, highlighting the questions they need to ask of product designers, managers, and distributors. It reflects the thinking and philosophy of ELSA’s members and is a key reason the association was established. ELSA looks forward to refining it further in the months and years ahead.

    Simon Erritt is a Managing Director of Coventry Capital


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2022 - October Commentary Life Settlements Longevity Risk Volume 1 Issue 6 - October 2022
    Share. Twitter LinkedIn Email

    Related Posts

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026By LMI Newsdesk

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026By Greg Winterton

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026By Fergus Bescoby

    Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

    August 6, 2026By LMI Newsdesk
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.